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Abstract: Gene silencing by siRNA (synthetic dsRNA of 21-25 nucleotides) is a well 
established biological tool in gene expression studies and has a promising therapeutic 
potential for difficult-to-treat diseases. Five fatty acids of various chain length and 
oxidation state (C12:0, C18:0, C18:1, C18:2, C22:1) were conjugated to the naturally 
occurring polyamine, spermine, and evaluated for siRNA delivery and gene knock-down. 
siRNA delivery could not be related directly to gene silencing efficiency as N4,N9-dierucoyl 
spermine resulted in higher siRNA delivery compared to N4,N9-dioleoyl spermine. GFP 
silencing in HeLa cells showed that the unsaturated fatty acid amides are more efficient 
than saturated fatty acid amides, with N4,N9-dioleoyl spermine resulting in the most 
efficient gene silencing in the presence of serum. The alamarBlue cell viability assay 
showed that fatty acid amides of spermine have good viability (75%–85% compared to 
control) except N4,N9-dilauroyl spermine which resulted in low cell viability. These results 
prove that unsaturated fatty acid amides of spermine are efficient, non-toxic, non-viral 
vectors for siRNA mediated gene silencing.  
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1. Introduction 
siRNA is a synthetic double-stranded (dsRNA) of 21-25 nucleotides per strand. Post-transcriptional 
gene silencing by siRNA is an important biological tool in functional genomics studies and has many 
potential therapeutic applications for difficult-to-treat diseases. After intracellular entry and subsequent 
release of siRNA in the cytoplasm, siRNA mediates sequence specific mRNA degradation. The 
process of gene silencing starts when siRNA is loaded in the RNA induced silencing complex (RISC), 
a complex of siRNA and other proteins (enzymes) among which is the endonuclease argonaute-2, the 
enzyme that catalyzes the degradation of mRNAs that have a complementary sequence to the siRNA 
loaded in the RISC. During the RISC loading, the passenger siRNA strand is cleaved and only the 
guide (anti-sense) strand is loaded. mRNA possessing a complementary sequence to the guide strand is 
then cleaved by the RISC. siRNA is a potential therapeutic for the treatment of many diseases such as 
thyroid papillary carcinoma [1] and osteoclast-mediated bone resorption [2], recently reviewed by 
Blagbrough and Zara [3]. Many clinical trials that involve siRNA or vectors expressing shRNA are 
now in phase I and phase II, e.g. RNAi assessment of Cand5 in diabetic macular edema (RACE) (Phase 
II), using intra vitreal injections of a siRNA in patients with age-related macular degeneration (Phase 
II), and a phase I open-label, rising-dose study of the safety and tolerability of single doses of NUC 
B1000 (http://www.wiley.com/legacy/wileychi/genmed/clinical/) which is an RNAi-based therapy for 
chronic hepatitis B. 
Nanoparticle formulation of siRNA as a platform for therapeutic applications has very recently been 
reviewed in this journal [4]. Cationic lipids are among the most widely used non-viral gene delivery 
vectors [5-12]. Cationic lipids are amphipathic molecules that are composed of a hydrophobic part and 
a cationic head group which may be attached to the hydrophobic part directly or through a linker 
[13,14]. The hydrophobic part of cationic lipids varies from alkyl or fatty acid (acyl) chains [15-17] to 
steroids, e.g. cholesterol [18,19]. The cationic head group should contain one or more functional 
groups that can acquire a positive charge at a physiological pH of 7.4 such as amines (primary, 
secondary, tertiary, and quaternary) [15,20], guanidines, imidazoles, or pyridinium salts [20]. The 
positive charge on the cationic head group interacts electrostatically with the negative charge of the 
phosphate backbone of the siRNA while the hydrophobic part of the cationic lipids promotes the 
formation of vesicles or siRNA/cationic lipid aggregates called lipoplexes. The hydrophobic moiety of 
cationic lipids can affect the siRNA delivery and the biological activity (gene knock-down) according 
to its physical and chemical properties such as chain length and saturation state. 
We have therefore designed a series of symmetrical diacyl lipopolyamines in order to prepare 
lipoplex formulations (without any pre-preparation of liposomes) of an Alexa Fluor 647-tagged siRNA 
to investigate if they are suitable for non-toxic transfection of target cells, by forming nanoparticles 
which will efficiently enter cells for non-viral gene therapy (NVGT) either by endocytosis (a major 
pathway) or possibly by endocytosis in combination with fusion between siRNA lipoplexes and the 
plasma membrane (a minor pathway) [9]. Such formulations of lipoplexes lead to RNA knock-down in 
which the siRNA binding is achieved by anion titration. Herein we report our investigations on 
formulations of siRNA with variation in the length of the two acyl fatty chains regiospecifically 
covalently bound to spermine. We report the synthesis of five symmetrical diacyl lipopolyamines, 
varying the chain length from lauroyl C12 to the very long chain erucoyl C22, and varying the 
Pharmaceutics 2011, 3                   
 
 
127
oxidation (saturation) state by including stearoyl (18:0), oleoyl (18:1), and linoleoyl (18:2) as well as 
the unsaturated erucoyl (22:1) spermine conjugate. We provide detailed evidence for the 
characterization of the nanoparticles, the delivery of Alexa Fluor 647-tagged siRNA and the silencing 
of GFP biosynthesis, the cell viability, and we compare our results with those obtained with cationic 
liposomal Lipofectamine 2000 and non-liposomal TransIT TKO. 
2. Experimental Section 
2.1. Materials and general methods 
Dicyclohexylcarbodiimide (DCC), 4-dimethylaminopyridine (DMAP), fatty acids, fatty acid 
chlorides, G418, hydrazine monohydrate, N-carbethoxyphthalimide, spermine, and triethylamine 
(TEA), were purchased from Sigma-Aldrich (Gillingham, UK). All solvents were purchased from 
Fisher Scientific UK (Loughborough, UK). Cell culture media were purchased from Gibco (Invitrogen 
Ltd, Paisley, UK). HeLa cells stably expressing GFP were obtained from the Cell Service at Cancer 
Research UK (CRUK, London Research Institute, Clare Hall Laboratories, South Mimms, London, 
UK). NMR spectra were recorded in chloroform-D using a Varian Mercury 400 (operating at 400 MHz 
for 1H and 100.8 MHz for 13C) spectrometer. The high resolution (HR) time-of-flight mass spectra 
were obtained on a Bruker Daltonics micrOTOF mass spectrometer using electrospray ionisation (ESI). 
AllStars negative control siRNA tagged with Alexa Fluor® 647 at the 3'-position was purchased from 
Qiagen (Crawley, UK) as was siRNA against GFP labelled with Alexa Fluor® 647 at the 3'-position of 
the sense strand, sequences:   
Sense strand: 5'-GCAAGCUGACCCUGAAGUUCAUTT-3',  
Anti-sense strand: 5'-AUGAACUUCAGGGUCAGCUUGCCG-3',  
Target DNA sequence: 5'-CGGCAAGCTGACCCTGAAGTTCAT-3'.  
2.2. Synthesis of fatty acid amides of spermine 
N-Carbethoxyphthalimide (0.44 g, 2 mmol) was added to a solution of 1,12-diamino-4,9-
diazododecane (spermine) (0.20 g, 1 mmol) in DCM (10 mL). The solution was stirred 20 °C for 3 h 
then evaporated to dryness in vacuo and the residue was used directly in the following step. To a 
solution of 1,12-diphthalimido-4,9-diazadodecane in DCM (10 mL) and TEA (0.28 mL, 2 mmol) fatty 
acid chloride (2 mmol), or alternatively fatty acid (2 mmol), DMAP (0.24 g, 2 mmol), and DCC (0.4 g, 
2 mmol) were added and stirred for 18 h under nitrogen atmosphere. The solvent was then evaporated 
to dryness in vacuo and the residue was treated with hydrazine monohydrate (2 mL) in a mixture of 
DCM (15 mL) and THF (15 mL) and heated under reflux for 4 h then the solvent was evaporated in 
vacuo to dryness and the residue purified over silica gel (DCM/MeOH 10:1 v/v then DCM/MeOH/ 
NH4OH 20:10:1 v/v/v) to afford the title compounds, which were then fully characterized by both 
high-field 1H and 13C NMR spectroscopy and HR-ESI-MS. 1H and 13C NMR data were comparable 
with literature data [21-23]. 1,12-Diphthalimido-4,9-diazadodecane, HRMS m/z, ESI found (M+1)+ 
463.2354, C26H31N4O4 requires (M+1)+ 463.2340. N4,N9-Dierucoylspermine, 1 [21], HRMS m/z, ESI 
found (M+1)+ 843.8355, C54H106N4O2 requires (M+1)+ 843.8316. N4,N9-Dilauroylspermine, 2 [22], 
HRMS m/z, ESI found (M+1)+ 567.5553, C34H70N4O2 requires (M+1)+ 567.5572. N4,N9-
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Dilinoleoylspermine, 3 [23], HRMS m/z, ESI found (M+1)+ 727.6851, C46H86N4O2 requires (M+1)+ 
727.6824. N4,N9-Dioleoylspermine, 4 [23], HRMS m/z, ESI found (M+1)+ 731.7174, C46H90N4O2 
requires (M+1)+ 731.7137. N4,N9-Distearoylspermine, 5 [23], HRMS m/z, ESI found (M+1)+ 
735.7428, C46H94N4O2 requires (M+1)+ 735.7450.  
2.3. Transfection studies of HeLa cells stably expressing GFP 
Cells were trypsinized at confluency 80–90% and were seeded at a density of 65,000 cells/well in 
24-well plates and were incubated for 24 h at 37 °C, 5% CO2, prior to transfection. The lipoplexes 
were prepared by mixing the specified amounts of the transfection reagent in OptiMEM serum-free 
medium (50 µL) with 15 µL of siRNA (1 µM) in OptiMEM serum-free medium. The solutions were 
mixed for 4 s by means of a vortex mixer. On the day of transfection, the lipoplex solutions were added 
to wells containing DMEM (10% FCS) to make the final volume in each well 1 mL. The plates were 
then incubated for 48 h at 37 °C, 5% CO2. siRNA against GFP used in these experiments has 24 base-
pairs, thus each molecule of siRNA contains 48 negative charges corresponding to 48 negatively 
charged phosphate groups in the siRNA backbone. The synthesized spermine fatty acid amides each 
contain two terminal primary amine groups which will be positively charged at physiological pH 7.4, 
therefore, each vector molecule carries two positive charges. N/P ratio is calculated using the following 
equation:  
48
2/
×
×
=
siRNAofmolesofnumber
lipidcationicofmolesofnumberPN  
2.4. Flow cytometry (FACS) 
For analysis of delivery and then reduction of expression of GFP by flow cytometry, cells were 
trypsinized and resuspended in complete medium without phenol red. Cells were centrifuged  
(1,000 rpm for 5 min), and washed twice by resuspending in PBS containing 0.1% BSA (1 mg/mL 
bovine serum albumin) then and centrifugation (1,000 rpm for 5 min). The collected cells was then 
resuspended in PBS and transferred to a flow cytometer tube (Becton Dickinson, UK). Cells (typically 
10,000–20,000 events) were then analyzed using a FACSCanto flow cytometer (Becton Dickinson, 
UK), equipped with an argon ion laser at 488 nm for excitation, a Long Pass (LP) filter at 502 nm and a 
detector at 530 nm (range +/−15 nm) for fluorescence emission, helium/neon laser at 633nm, and 
detector for the Alexa Fluor 647 at 660 nm (range +/− 10 nm). GFP expression is calculated as:   
100% ×=
cellscontrolofcefluorescenGFP
cellsdtransfecteofcefluorescenGFPGFP   
2.5. Confocal microscopy cell imaging 
Cells were trypsinized at confluency 80–90% and were seeded at a density of 65,000 cells/well in 
24-well plates that have a round-glass cover slip (12 mm in diameter) and were incubated for 24 h prior 
to transfection which was carried out as described above (Section 2.3). After 48 h, the cell culture 
media, in each well, were aspirated and the cells washed with PBS (3 × 0.5 mL). The cell membrane 
was then stained with wheat germ agglutinin (WGA) conjugated to Alexa Fluor® 555. The 
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concentration of WGA-Alexa Fluor® 555 working solution was adjusted to a concentration of 5 µg/mL 
in Hank’s balanced salt solution without phenol red. The cells were incubated for 10 min in the dye 
working solution at 37 °C, 5% CO2 in the dark. The cells were washed with PBS (3 × 0.5 mL) and then 
fixed with 4% paraformaldehyde in PBS solution for 20 min at 20 °C in the dark. The cover slips were 
then removed from each well, washed with PBS (2 × 0.5 mL), left to dry briefly in air, and then 
mounted on glass slides using Mowiol (polyvinyl alcohol) solution as the mounting media and left in 
the dark at 20 °C (18 h) to allow hardening of the mounting media. The cells were examined using a 
Carl Zeiss laser scanning microscope LSM 510 meta, with GFP excitation 488 nm, emission  
505–550 nm (band pass filter), Alexa Fluor® 555 excitation 543 nm, emission 560–615 nm (band pass 
filter), and Alexa Fluor® 647 excitation 633 nm, emission 657–753 nm (meta detector). 
 
2.6. Cell viability assay 
 
Cells were seeded at a density of 6,500 cells per well of 96-well plates. The transfection was carried 
out using the same protocol as transfecting the 24-well plates with the exception of reducing the 
amount of lipoplexes such that each well contains 1.5 pmol siRNA in a final volume of 100 µL/well. 
After 44 h, alamarBlue® [24] (10 µL) was added to each well. After incubation (3.5 h), the absorbance 
of each well was measured at 570 nm and 600 nm and calculations were carried out according to the 
standard protocol provided by the supplier. 
 
2.7. Particle size and zeta potential measurements 
 
Lipoplexes were prepared by adding siRNA solution (75 µL, 1 µM) in HEPES (pH 7.4, 10 mM) to 
HEPES (250 µL) containing the specified amount of transfection reagent followed by vortex mixing 
for 4 s. Samples were then diluted to a final volume of 3 mL by HEPES buffer. Samples were mixed 
for 10 s directly before measurements. Measurements were carried out using Malvern Zetasizer Nano 
S90 using refractive index 1.59, viscosity 0.89 cP, dielectric constant 79, and temperature set to 25 °C 
with equilibrium time 3 min. Z-Average diameter in nm and zeta potential in mV were recorded as 
averages of three and six measurements respectively. 
3. Results and Discussion 
3.1. Synthesis of fatty acid amides of spermine 
Spermine (N,N′-bis(3-aminopropyl)-1,4-diaminobutane) was used as the starting material to 
synthesize the five desired fatty acid amide conjugates: N4,N9-dierucoyl spermine 1, N4,N9-dilauroyl 
spermine 2, N4,N9-dilinoleoyl spermine 3, N4,N9-dioleoylspermine 4, and N4,N9-distearoyl spermine 5 
(Table 1 and Figure 1). The two terminal primary amine groups of spermine were chemo-selectively 
protected with phthalimido protecting groups (2 eq. in CH2Cl2). The fatty acids were conjugated to the 
N4- and N9-position of the diphthalimido protected spermine by one of two methods, either fatty acyl 
chloride (lauroyl, oleoyl, or stearoyl) (2 eq.) and triethylamine (2 eq.) or alternatively fatty acid (erucic 
or linoleic) (2 eq.), DCC (2 eq.), DMAP (2 eq.) were added to the diphthalimido protected spermine 
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solution in anhydrous CH2Cl2. After the completion of conjugation reaction as followed by TLC, the 
solution is filtered and residue is dissolved in 1:1 mixture of CH2Cl2/THF. Refluxing with hydrazine  
(2 mL) resulted in deprotection of the primary amine groups. The required fatty acid conjugates of 
spermine were purified by flash silica column chromatography to homogeneity by TLC. Confirmation 
of the structures of the pure target cationic lipids 1-5 followed from HRMS and comparison of their 1H 
and 13C NMR spectroscopic data with those in the literature [21-23]. 
Table 1. N4,N9-difatty acid amides of spermine. The fatty acids are described by two 
numbers separated by a colon, first the chain length and then the number of double bonds. 
Particle size and ζ-potential of fatty acid amides of spermine measured at the cationic 
lipid/siRNA ratios that showed best knock-down. 
Name of compound Fatty acid Description 
of fatty acid 
Particle size 
(nm) ± SD 
Zeta-potential 
(mV) ± SD 
N4,N9-Dierucoylspermine 1 Erucic 22:1 192 ± 1 63 ± 4 
N4,N9-Dilauroylspermine 2 Lauric 12:0 283 ± 41 25 ± 4 
N4,N9-Dilinoleoylspermine 3 Linoleic 18:2 353 ± 8 54 ± 1 
N4,N9-Dioleoylspermine 4 Oleic 18:1 247 ± 4 54 ± 1 
N4,N9-Distearoylspermine 5 Stearic 18:0 145 ± 24 41 ± 7 
Figure 1. N4,N9-Difatty acid amides of spermine. 
  1 
  2 
  3 
  4 
  5 
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3.2. Lipoplex particle size and ζ-potential 
 
The particle size and ζ-potential (Table 1) measurements were carried out on the lipoplexes at the 
cationic lipid/siRNA ratio which gave the best knock-down for the specified fatty acid amide of 
spermine. Particle size characterization by dynamic light scattering showed that the particle size of the 
formed lipoplexes varied from 145 to 353 nm which is within the size range for lipoplexes required for 
siRNA and/or DNA delivery, probably via endocytosis. The largest lipoplex diameter (353 nm) was 
obtained with 3 while the smallest (145 nm) was obtained with 5. There was no obvious direct 
relationship between the lipoplex particle size and either the ratio of cationic lipid/siRNA or the 
characteristics (chain length and/or oxidation state) of the fatty acid used. The ζ-potentials of the 
lipoplexes were all positive (+25–63 mV), thus playing a role in the stabilization of the lipoplexes by 
imparting repulsion between the formed lipoplexes and preventing their aggregation. The positive 
charge of the lipoplexes also facilitates interaction with the negatively charged cell membrane. 
 
3.3. Transfection with siRNA and evaluation of delivery and knock-down 
 
HeLa cells [25] are often used as a target for proof of principle of transfection efficiency [8,26]. 
Lipoplexes prepared with the synthetic fatty acid spermine conjugates 1-5 and siRNA tagged with the 
fluorescent dye Alexa Fluor 647 were delivered to modified HeLa cells that stably express GFP in 
order to evaluate both the delivery of siRNA and the knock-down of GFP expression. Both the delivery 
of siRNA and GFP knock-down were evaluated by calculating the geometric mean fluorescence of 
Alexa Fluor 647 and GFP by means of flow cytometry (FACS analysis) after gating the population of 
healthy cells (Figure 2a). The increase in Alexa Fluor 647 fluorescence within the gated population (i.e. 
delivery of fluorescent siRNA) and the decrease in GFP fluorescence (i.e. knock-down) are shown in 
Figure 2b-2e. Populations P4 and P5 are set for the calculation of the geometric mean fluorescence. 
The amount of Alexa Fluor 647 fluorescence 48 h post-transfection was used to evaluate the relative 
efficiency of siRNA delivery by the lipospermine conjugates. Lipoplexes of 1 showed the highest 
Alexa Fluor 647 fluorescence (159 units) at 6 µg of 1 (Figure 3, upper). Lipoplexes of 4 were second 
(17 units) at 6 µg of 4 (Figure 3, lower). Typically, there is a relationship between the amount of each 
fatty acid spermine conjugate and the intensity of the Alexa Fluor 647 fluorescence measured, except 
for 2 at 0.75–3 µg and for 3 at 1.5 and 3 µg. Thus, increasing the amount of cationic lipid, from 0.75 to 
6 µg, gave an increase in Alexa Fluor 647 fluorescence (Figure 3, upper and lower). 
Fatty acids with longer chain lengths and one C=C (erucoyl 22:1 and oleoyl 18:1) resulted generally 
in higher fluorescence at the same amount of lipid used. The least fluorescence was obtained with 2 
(lauroyl 12:0) (Figure 3, lower) which is saturated and has a relatively shorter chain length. 
Reduction in GFP expression (Figures 4 and 5) was best achieved by lipoplexes of 4 (19% at 6 µg 
cationic lipid and 22% at 3 µg) followed by 3 (28% at 1.5 µg). These values are comparable with the 
commercial agents Lipofectamine 2000 and TransIT TKO (both 24%). Lipoplexes of 1 resulted in 
modest reduction of GFP (43% at 6 µg). Lipoplexes of the saturated fatty acid conjugates 2 and 5 
resulted in the lowest knock-down (highest GFP expression) with values of 80% and 69% respectively. 
The overall better efficiency of unsaturated fatty acid spermine amides in reducing GFP expression is 
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attributed to the effects of double bonds restricting chain flexibility, allowing better interaction with the 
cell membrane lipids. We have reported [23] the effect of unsaturation of spermine fatty acid 
conjugates on their ability to transfect primary skin cell lines (FEK4, FCP4, FCP5, FCP7, and FCP8) 
and the cancer cell line HtTA transfected with pEGFP using the C18 derivatives of spermine linoleoyl 
(18:2), oleoyl (18:1), and stearoyl (18:0). The unsaturated oleoyl 4 and linoleoyl 3 spermine conjugates 
were found to be much more efficient (3-5-fold) than the stearoyl 5 spermine conjugate. Higher 
fusogenic ability of unsaturated fatty acids (especially in the cis-configuration) probably favors (Lα to 
HII) transition. A similar conclusion was reported [27] where unsaturated fluorinated lipospermines 
were more efficient than their saturated analogues due to the ability of unsaturated derivatives to 
promote membrane fusion and endosomal escape. 
Figure 2. (a) The gating of a population of healthy cells. (b) Alexa Fluor 647 channel 
autofluorescence of control cells. (c) GFP expression of control cells. (d) Alexa Fluor 647 
fluorescence after transfection with 4 at 6 µg/well. (e) GFP expression after transfection 
with 4 at 6 µg/well. 
 
(a) 
    
(b)       (c) 
    
(d)       (e) 
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Figure 3. Upper: siRNA delivery using 1. Values are presented as mean of normalized 
geometric mean fluorescence ± SD (n = 6). Lower: siRNA delivery measured as the 
normalized values of Alexa Fluor 647 (AF) geometric mean fluorescence using 2-5. 
0
50
100
150
200
0.75 1.5 3 6
A
F
 
fl
u
o
re
s
c
e
n
c
e
 
 
 
 
Erucoyl µg/well  
Erucoyl 1
 
0
5
10
15
20
25
0.75 1.5 3 6
A
F 
flu
o
re
s
c
e
n
c
e
 
 
 
 
Cationic lipid µg/well  
Lauroyl 2
Linoleoyl 3
Oleoyl 4
Stearoyl 5
 
 
There was no obvious direct relationship between the particle size and the efficiency of delivery or 
knock-down. The particle size of lipoplexes formed with vectors 2 and 4 were 283 and 247 nm 
respectively, but 2 resulted in less delivery (3 units compared to 17 units of 4) and lower reduction in 
GFP expression. Lipoplexes of 3 had larger particle size than 4 (353 and 247 nm respectively) and 3 
showed less GFP reduction compared to 4. On the other hand, though lipoplexes of 5 had the lowest 
diameter (145 nm), they showed less reduction in GFP (to 69%) compared to 3 and 4 (to 28% and to 
19% respectively). These results show that, while keeping particle size within the normal lipoplex 
transfection range, particle size is not the only significant factor. Vectors 3, 4, and 5 have the same 
chain length while they differ in oxidation (saturation) state (18:2, 18:1, and 18:0 respectively). 
The amount of siRNA delivered was evaluated by the fluorescence of Alexa Fluor 647 remaining 
after 48 h post transfection. There was no direct relationship between the amount of siRNA delivered 
and the knock-down efficiency. Lipoplexes of 1 resulted in the highest delivery (159 units at 6 µg) and 
GFP reduction (43%) while lipoplexes of 4 resulted in less siRNA delivery (17 units at 6 µg) and GFP 
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reduction (19%) at the same amount of cationic lipid. The same can be said with respect to 3 (GFP 
reduction to 28% at 1.5 µg and delivery 3 units only) compared to 1. However, with respect to vectors 
1, 4, and 5, the increase of Alexa Fluor 647 fluorescence is accompanied by better reduction in GFP. 
These observations can be related to the different barriers to successful knock-down. Lipoplexes must 
first be internalized inside the cells (probably by endocytosis) followed by release from the endosomes 
before turning into lysosomes, then the release of siRNA in the cytoplasm to integrate with the RNAi 
machinery and promote the sequence specific gene silencing. Thus, it is not a necessity that a higher 
number of lipoplexes (i.e. more siRNA gets into the cells) corresponds to an increase in gene knock-
down, because successful knock-down will require the success of all the aforementioned steps. 
Figure 4. Reduction in GFP expression in HeLa cells after transfection with lipoplexes of 
fatty acid amides of spermine at different cationic lipid/siRNA ratios. siRNA concentration 
is kept constant at 15 pmol/well. Values are presented as mean ± SD (n = 6). 
 
 
Figure 5. Comparison of reduction in GFP expression in HeLa cells (knock-down) at their 
optimal cationic lipid/siRNA ratios (shown as µg cationic lipid/15 pmol siRNA/well) and 
compared with the commercially available transfection agents Lipofectamine 2000  
(2 µL/well) and TransIT TKO (4 µL/well). Values are presented as mean ± SD (n = 6) 
using erucoyl (6 µg/well), linoleoyl (1.5 µg/well), oleoyl (6 µg/well), and stearoyl  
(6 µg/well). 
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Figure 6. GFP percentage expression 48 h post transfection with scrambled negative 
control siRNA. Numbers in brackets are siRNA delivery expressed as Alexa Fluor® 647 
normalized geometric mean fluorescence ± SD. 
 
Figure 6 shows the effect of transfecting HeLa cells with AllStars negative control siRNA at the 
optimum cationic lipid/siRNA ratios that resulted in the best GFP knock-down with respect to each of 
the spermine conjugate vectors. Although there was an increase in the levels of fluorescence of Alexa 
Fluor® 647, there was no corresponding significant decrease in the GFP expression levels, except for 
compound 2 which is relatively toxic (as discussed below in Section 3.5). This indicates that the 
reduction of GFP fluorescence levels when transfecting with siRNA directed against GFP is due to the 
sequence-specific gene silencing mediated by the siRNA and not due to any cytotoxic or non-specified 
effects of the vector. The scrambled siRNA is reported by the manufacturer to lack homology to any 
mammalian genes and it also did not result in significant changes in GFP expression due to off-target 
effects. siRNA against GFP with sequence 5'-GCAAGCUGACCCUGAAGUUCAUTT-3' sense strand 
and 5'-AUGAACUUCAGGGUCAGCUUGCCG-3' anti-sense strand has one report of off-target 
effects that might affect gene-expression in HeLa and HEK cell lines [26]. The target DNA homology 
for silencing GFP is 5'-CGGCAAGCTGACCCTGAAGTTCAT-3'.  
3.4. Confocal microscopy cell imaging 
 
Vector 4 was used to prepare lipoplexes with Alexa Fluor® 647 labeled AllStars negative control 
siRNA and siRNA against GFP at N/P = 22, the optimum ratio for the best GFP knock-down  
(6 µg/15 pmol siRNA). Figure 7a shows the control HeLa cells (non-transfected) showing the bright 
green fluorescence of GFP and the cell membrane stained with WGA-Alexa Fluor® 555 (in blue). 
Figure 7b shows the HeLa cells 48 h post transfection where the fluorescence of GFP is significantly 
reduced and bright red spots indicate the fluorescence of Alexa Fluor® 647 tagged siRNA, showing the 
uptake of the tagged siRNA. Figure 7d shows a magnified image of one cell (from Figure 7b) where 
many red spots show the uptake of the Alexa Fluor® 647 and the absence of any green color, the 
obvious reduction in GFP expression. Figure 7c shows HeLa cells 48 h post transfection with AllStars 
negative control siRNA, the red spots indicate cellular uptake of the tagged siRNA with no noticeable 
difference in GFP fluorescence relative to the control HeLa cells (Figure 7a). Figure 7c is evidence that 
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the reduction in GFP (seen in Figure 7b and 7d) is due to the sequence specific gene silencing by the 
siRNA against GFP and not due to cytotoxic or non-specified effects of N4,N9-dioleoylspermine 4. 
Figure 7. Confocal microscopy cell imaging. GFP fluorescence (green), cell membrane 
stained with WGA-Alexa Fluor® 555 (blue), and Alexa Fluor® 647 (red) represents tagged 
siRNA delivered with N4,N9-dioleoylspermine 4. (a) non-transfected HeLa cells (control); 
(b, d) HeLa cells 48 h post transfection with siRNA against GFP; (c) HeLa cells transfected 
with AllStars negative control siRNA. 
 
    7a      7b 
 
    7c      7d 
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3.5. Cell viability assay 
 
The cell viability assay was carried out in 96-well plates. In order to keep the viability assay 
conditions as close as possible to the conditions used in the knock down experiments which were 
carried out in 24-well plates, the amounts of siRNA and cationic lipid, and the number of cells/well 
were multiplied by the same factor (one-tenth), thus maintaining the N/P ratio and the amount of 
siRNA per total number of cells constant while downscaling from the 24-well format to the 96-well 
format. Thus, the 24-well format used 15 pmol siRNA/well, 6 µg cationic lipid/well, and  
65,000 cells/well, and the 96-well format used 1.5 pmol siRNA/well, 0.6 µg cationic lipid/well, and 
6,500 cells/well. 
Cell viability evaluation after transfection was carried out with the alamarBlue assay. It can be seen 
from the upper panel in Figure 8 that increasing the amount of lipid vector (from 0.075 µg to 0.6 µg) 
was accompanied by a decrease in cell viability. Short chain 2 (lauroyl, 12:0) was much more toxic 
than the other four spermine conjugates, at 6 µg of 2 there was only 3% cell viability. The cell viability 
with dilauroyl 2 is lower than that of N4,N9-dioleoyl 4 or distearoyl 5 spermine used to transfect HtTA 
cell line with a scrambled (negative control) fluorescein-labeled siRNA [17]. Indeed, we showed, using 
the MTT cell viability assay, that the fatty acid conjugates of spermine with shorter chain length (C12-
C16) resulted in lower cell viability than the C18 fatty acid spermine conjugates [22]. The lower panel 
in Figure 8 shows that, with the exception of 2, our fatty acid spermine amides were at least as well 
tolerated as the commercially available reagents Lipofectamine 2000 and TransIT TKO in HeLa cells. 
 
Figure 8. Upper: Cell viability alamarBlue assay of fatty acid amides of spermine at 
different cationic lipid/siRNA ratios. siRNA concentration is kept constant at  
1.5 pmol/well (n = 6). Lower: Comparison of cell viability of HeLa cells after transfection 
with fatty acid amides of spermine at their optimal cationic lipid/siRNA ratios and 
compared with the commercially available transfection agents Lipofectamine 2000 and 
TransIT TKO Values are presented as mean ± SD (n = 6) using erucoyl (0.6 µg/well), 
linoleoyl (0.15 µg/well), oleoyl (0.6 µg/well), and stearoyl (0.6 µg/well). 
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Figure 8. Cont. 
 
4. Conclusions 
Saturated short chain (C12:0) 2 showed concentration dependant toxicity when compared with the 
longer chain (C18-C22) spermine fatty acid amides. Transfection with lipoplexes of siRNA and N4,N9-
difatty acid amides of spermine resulted in successful transfection and gene silencing of GFP in HeLa 
cells. Varying the chain length or oxidation state of the fatty acids affected both the siRNA delivery 
and gene silencing efficiency with non-saturated fatty acids (C18:1), (C18:2), and (C22:1) being more 
efficient compared to saturated fatty acids (C12:0) and (C18:0). There was no evidence for a direct 
relationship between the amount of siRNA delivered and the extent of gene silencing. N4,N9-
dilinoleoyl spermine 3 and N4,N9-dioleoyl spermine 4 were at least as efficient and as well tolerated 
(high cell viability) as the commercially available market leaders Lipofectamine 2000 and TransIT 
TKO. These optimized SAR studies demonstrate that N4,N9-difatty acid amides of spermine are 
efficient, non-viral siRNA delivery vectors in vitro for HeLa cells. 
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